ÂÜÀòÂÒÂ×

Bing Lim, MD, PhD has an extensive work experience spanning several prestigious institutions. Starting in 1988, they worked as an Associate Physician at Beth Israel Deaconess Medical Center until 2014. During this time, Dr. Lim identified novel hematopoietic-specific genes and played a key role in the research on ras-related small RhoGTPases. Bing also utilized embryonic stem cells and genomics to determine the genes that define "stemness" in embryonic stem cells.

In 1993, Dr. Lim became an Associate Professor of Medicine at Harvard Medical School and conducted research at Beth Israel Deaconess Medical Center. Bing furthered their exploration of hematopoietic function and development, cloning and identifying novel hematopoietic-specific genes. Their work on identifying a family of GDP-dissociation inhibitors and proposing a nomenclature for them continues to be influential.

From 2003 to 2018, Dr. Lim assumed various roles at A*STAR - Agency for Science, Technology and Research, including Senior Group Leader (Stem Cell and Developmental Biology) and Associate Director (Cancer Stem Cell Biology). Their research achievements during this time include establishing the genome institute's stem cell research program and mapping gene regulatory networks controlling stem cell functions. Bing also made significant discoveries regarding reprogramming differentiated skin cells into induced pluripotent stem cells and the unique characteristics of human lung adenocarcinoma cancer stem cells.

In 2014, Dr. Lim joined Merck as the Associate Vice President for Research Science and Translational Medicine. Bing played a vital role in transforming the Merck Translational Medicine Research Centre into an early discovery and preclinical development center. Bing also conceived and built the Translational Oncology team, focusing on catalyzing innovation and translating discoveries into therapeutics.

After their tenure at Merck, Dr. Lim joined Sana Biotechnology, Inc. in 2019 as the Senior Vice President for Cell Therapy. Their expertise in cell therapy contributed to the company's endeavors. Currently, they hold the position of Chief Scientific Officer at Thymmune Therapeutics, starting in 2021.

Bing Lim, MD, PhD, began their education at the University of Toronto, where they earned their Doctor of Philosophy (PhD) in Cell and Molecular Biology in 1985. Bing then pursued further training at Harvard Medical School, serving as a Post-Doctoral Research Fellow in Retroviral Gene Therapy. Following this, Bing Lim returned to the University of Toronto as a Fellow in Hematology/Oncology. Later, they attended the University of Western Ontario, where they obtained their Doctor of Medicine (MD) degree.